AOA Dx is a startup based in the United States. Brouky records 2 investors associated with the company.
AOA Dx develops AI-enabled blood tests for early detection of ovarian cancer and other women’s health cancers using a multi-omics platform (GlycoLocate) and lipidomics-based biomarkers (AKRIVIS GD™). The company combines lipidomics, other complementary biomarkers, and data science to identify early-stage disease from blood samples.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.